CG Oncology Beats Q3; Insider Sells For Third Month
CG Oncology beat Q3 earnings estimates with a net loss of $0.64 per share versus the FactSet consensus of $0.84. An insider sold shares in three consecutive months while the stock fell 17%, raising qu
CG Oncology Beats Q3 Estimates; Insider Exits Third Month
NEW YORK, November 8 —
Even as CG Oncology, Inc. (CGON) posted a Q3 net loss of $0.64 per share, beating the FactSet consensus of $0.84, a single insider sold shares in three consecutive months without one open-market purchase. The disposals tracked a price slide from $74.54 in August to roughly $62 in October, ending weeks before the Q3 results became public.
- Q3 net loss $0.64/share beat the FactSet consensus of $0.84; $984.5M in cash and securities as of quarter-end.
- Insider Leonard E Post sold shares on August 14, September 15, and October 15 via option-exercise-and-immediate-sell transactions.
- Net insider open-market purchases over 90 days: zero; Post's total open-market sales: approximately $0.21 million.
Four Trials, Zero Revenue
CG Oncology develops cretostimogene grenadenorepvec, an oncolytic immunotherapy targeting bladder cancer patients who have failed BCG therapy, a population with limited alternatives. The company generates effectively no commercial revenue, running four active late-stage programs simultaneously: two Phase 3 BOND-003 cohorts for BCG-unresponsive disease, the Phase 3 PIVOT-006 adjuvant trial, and Phase 2 CORE-008 for high-risk patients including BCG-naïve cases. With trailing twelve-month operating cash flow of -$178 million, the $984.5 million cash balance provides roughly five years of runway at the current burn rate, though a securities offering filed alongside Q2 earnings in August shows the company's comfort with that math.
The Selling Pattern
What makes the insider activity worth examining is not any single transaction but the regularity. Leonard E Post exercised options at $0.60 per share and immediately sold the acquired shares each month: 1,000 shares at $74.54 on August 14, 1,000 shares at $72.98 on September 15, and 1,000 shares split across two tranches at $61.65 and $62.48 on October 15, per Form 4 filings with the SEC. Option-exercise-and-sell programs are common and may reflect pre-planned diversification rather than a directional view. Harder to explain is the absence of any open-market purchase over those 90 days, particularly in October when the stock had fallen roughly 17% from August levels.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| CGON | $6.7B | n/a | +88.9% |
| AVBP | $673M | n/a | -26.7% |
| SYRE | $9.9B | n/a | +368.3% |
| MLYS | $1.4B | n/a | -65.6% |
| EWTX | $4.9B | n/a | +146.4% |
| ELVN | $3.6B | n/a | +164.2% |
The Trials Decide the Multiple
The stock trades at $75.99 against an analyst consensus target of $91.61, roughly 20% implied upside, while institutional ownership sits at a reported 113.2% of shares outstanding, a figure that often reflects significant short-selling and rehypothecation rather than straightforward conviction. Short interest at 10.2% of float confirms the two-sided positioning. The clinical thesis resolves through data, not quarterly expense management: readouts from the BOND-003 and PIVOT-006 programs would force the market to price the probability of regulatory approval more precisely. A DCF calculator applied to any peak-sales scenario here depends entirely on assumptions those trials will determine. Run the free CG Oncology, Inc. deep-dive → for the latest numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did CG Oncology beat Q3 earnings?
Yes. The company posted a Q3 net loss of $0.64 per share, beating the FactSet consensus estimate of $0.84. CG Oncology reported $984.5 million in cash and securities as of quarter-end.
Why did the insider sell CG Oncology shares for three months?
Leonard E Post exercised stock options and immediately sold shares on August 14, September 15, and October 15. Option-exercise-and-sell programs are common diversification tools that may not signal a directional negative view.
How long can CG Oncology operate with its current cash?
With trailing twelve-month operating cash flow of negative $178 million and $984.5 million in cash, the company has roughly five years of runway at the current burn rate. A securities offering filed in August suggests management is familiar with these economics.
What cancer program is CG Oncology developing?
The company develops cretostimogene grenadenorepvec, an oncolytic immunotherapy targeting bladder cancer patients who have failed BCG therapy. The company is running four active late-stage programs: two Phase 3 BOND-003 cohorts, Phase 3 PIVOT-006, and Phase 2 CORE-008.
What is the stock price target?
Analyst consensus price target is $91.61 against a current trading price of $75.99, implying roughly 20% upside. Clinical trial readouts from BOND-003 and PIVOT-006 will ultimately determine the market's probability assessment on regulatory approval.
CG Oncology reported a Q3 2026 net loss of $0.64 per share, beating the FactSet consensus estimate of $0.84 and holding $984.5 million in cash to fund its bladder-cancer immunotherapy pipeline. What complicates the picture: a company insider sold shares every month for three consecutive months through August, September, and October — with October sales at prices well below his August level — without making a single open-market purchase.